CN1056684A - 异唑-4-羧酰胺及羟基亚烷基氰乙酰胺,含有这些化合物的药物及它们的应用 - Google Patents
异唑-4-羧酰胺及羟基亚烷基氰乙酰胺,含有这些化合物的药物及它们的应用 Download PDFInfo
- Publication number
- CN1056684A CN1056684A CN91103182A CN91103182A CN1056684A CN 1056684 A CN1056684 A CN 1056684A CN 91103182 A CN91103182 A CN 91103182A CN 91103182 A CN91103182 A CN 91103182A CN 1056684 A CN1056684 A CN 1056684A
- Authority
- CN
- China
- Prior art keywords
- carbon atom
- alkyl
- chlorine
- bromine
- fluorine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/23—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and carboxyl groups, other than cyano groups, bound to the same unsaturated acyclic carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
- C07C317/40—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Air Conditioning Control Device (AREA)
- Photoreceptors In Electrophotography (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims (12)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4016178 | 1990-05-18 | ||
DEP4016178.1 | 1990-05-18 | ||
DE4017043 | 1990-05-26 | ||
DEP4017043.8 | 1990-05-26 | ||
DE4017020 | 1990-05-26 | ||
DEP4017020.9 | 1990-05-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1056684A true CN1056684A (zh) | 1991-12-04 |
CN1051074C CN1051074C (zh) | 2000-04-05 |
Family
ID=27201216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN91103182A Expired - Lifetime CN1051074C (zh) | 1990-05-18 | 1991-05-16 | 异噁唑-4-羧酰胺及羟基亚烷基氰基乙酰胺用于制备药物的用途 |
Country Status (28)
Country | Link |
---|---|
US (2) | US5494911A (zh) |
EP (1) | EP0527736B1 (zh) |
JP (3) | JP2995086B2 (zh) |
KR (1) | KR100188801B1 (zh) |
CN (1) | CN1051074C (zh) |
AT (1) | ATE151633T1 (zh) |
AU (2) | AU649421B2 (zh) |
BR (1) | BR9008022A (zh) |
CA (1) | CA2083179C (zh) |
CY (1) | CY2123B1 (zh) |
CZ (4) | CZ290474B6 (zh) |
DE (1) | DE59010701D1 (zh) |
DK (1) | DK0527736T3 (zh) |
ES (1) | ES2102367T3 (zh) |
FI (1) | FI105683B (zh) |
GR (1) | GR3023638T3 (zh) |
HU (1) | HU222234B1 (zh) |
IE (1) | IE911694A1 (zh) |
IL (1) | IL98163A (zh) |
LV (1) | LV10575B (zh) |
NO (1) | NO180118C (zh) |
NZ (1) | NZ238165A (zh) |
PT (1) | PT97689B (zh) |
RU (2) | RU2084223C1 (zh) |
SK (3) | SK281318B6 (zh) |
TW (2) | TW211558B (zh) |
WO (1) | WO1991017748A1 (zh) |
YU (1) | YU48765B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1065744C (zh) * | 1994-01-07 | 2001-05-16 | 休正公司 | 对与血小板源生长因子有关的疾病如癌症的治疗 |
CN1120160C (zh) * | 1997-01-28 | 2003-09-03 | 阿文蒂斯药物德国有限公司 | 异噁唑与巴豆酰胺衍生物及其在药学和诊断学中的用途 |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ235563A (en) * | 1989-10-13 | 1993-04-28 | Merck & Co Inc | Fibrinogen receptor antagonist and pharmaceutical composition |
GB9200275D0 (en) * | 1992-01-08 | 1992-02-26 | Roussel Lab Ltd | Chemical compounds |
GB9300083D0 (en) * | 1993-01-05 | 1993-03-03 | Roussel Lab Ltd | Chemical compounds |
ATE174220T1 (de) * | 1993-01-08 | 1998-12-15 | Hoechst Ag | Verwendung von leflunomid zur hemmung von interleukin 8 |
ATE174219T1 (de) * | 1993-01-08 | 1998-12-15 | Hoechst Ag | Verwendung von leflunomid zur hemmung von tumornekrosefaktor alpha |
ATE174217T1 (de) * | 1993-01-08 | 1998-12-15 | Hoechst Ag | Verwendung von leflunomid zur hemmung von interleukin 1 alpha |
EP0607775B1 (de) * | 1993-01-08 | 1998-12-09 | Hoechst Aktiengesellschaft | Verwendung von Leflunomid zur Hemmung von Interleukin 1 beta |
TW314467B (zh) * | 1993-03-31 | 1997-09-01 | Hoechst Ag | |
GB9313365D0 (en) * | 1993-06-29 | 1993-08-11 | Roussel Lab Ltd | Chemical compounds |
DE4323636A1 (de) * | 1993-07-15 | 1995-01-19 | Hoechst Ag | Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung |
GB9322781D0 (en) * | 1993-11-04 | 1993-12-22 | Roussel Lab Ltd | Aromatic amides |
US6335356B1 (en) | 1994-01-07 | 2002-01-01 | Sugen, Inc. | Method of treating a patient by parenteral administration of a lipophilic compound |
US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
US5721277A (en) * | 1995-04-21 | 1998-02-24 | Sugen, Inc. | Compounds and methods for inhibiting hyper-proliferative cell growth |
US6331555B1 (en) | 1995-06-01 | 2001-12-18 | University Of California | Treatment of platelet derived growth factor related disorders such as cancers |
GB9520092D0 (en) * | 1995-10-02 | 1995-12-06 | Hoechst Roussel Ltd | Chemical compounds |
DE19539638A1 (de) * | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
DE19547648A1 (de) * | 1995-12-20 | 1997-06-26 | Hoechst Ag | Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate |
DK0795334T3 (da) * | 1996-03-12 | 2006-06-06 | Sanofi Aventis Deutschland | Nye prodrugs til behandling af tumorer og betændelsessygdomme |
DE19610955A1 (de) * | 1996-03-20 | 1997-09-25 | Hoechst Ag | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid |
US6011051A (en) * | 1996-07-31 | 2000-01-04 | Hoechst Aktiengesellschaft | Use of isoxazole and crotonamide derivatives for the modulation of apoptosis |
CA2264798A1 (en) | 1996-09-04 | 1998-03-12 | Pfizer Inc. | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
CA2302438A1 (en) * | 1997-05-19 | 1998-11-26 | Sugen, Inc. | Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders |
US6316479B1 (en) | 1997-05-19 | 2001-11-13 | Sugen, Inc. | Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders |
ATE207065T1 (de) * | 1997-08-08 | 2001-11-15 | Aventis Pharma Gmbh | Kristallform von n-(4-trifluormethylphenyl)-5- methylisoxazol-4-carbonsäureamid |
CA2309175A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
MXPA00010150A (es) * | 1998-04-17 | 2002-05-14 | Parker Hughes Inst | Inhibidores de btk y metodos para su identificacion y uso. |
US6303652B1 (en) | 1998-08-21 | 2001-10-16 | Hughes Institute | BTK inhibitors and methods for their identification and use |
US6355678B1 (en) * | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
DE19908527C2 (de) * | 1999-02-26 | 2001-08-30 | Aventis Pharma Gmbh | Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid |
CN1411373A (zh) * | 1999-12-16 | 2003-04-16 | 特瓦制药工业有限公司 | 制备来氟米特的新方法和新晶形的来氟米特 |
US7217722B2 (en) * | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
ATE292966T1 (de) * | 2000-02-15 | 2005-04-15 | Teva Pharma | Methode zur synthetisierung von leflunomid |
US20030055263A1 (en) * | 2001-07-11 | 2003-03-20 | Boehringer Ingelheim Pharma Kg | Carboxylic acid derivatives, medicaments comprising these compounds, their use and processes for their production |
DE10133665A1 (de) * | 2001-07-11 | 2003-01-30 | Boehringer Ingelheim Pharma | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung |
EP1487796A4 (en) * | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
US6858637B2 (en) | 2002-03-28 | 2005-02-22 | Neurogen Corporation | Substituted biaryl amides as C5a receptor modulators |
US20050215614A1 (en) * | 2002-10-15 | 2005-09-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
PT1768966E (pt) | 2004-06-17 | 2012-05-23 | Infinity Discovery Inc | Compostos e métodos para inibir a interacção de proteínas bcl com parceiros de ligação |
US7842815B2 (en) | 2004-06-17 | 2010-11-30 | Infinity Pharmaceuticals, Inc. | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
DE102006014165A1 (de) * | 2006-03-24 | 2007-09-27 | Schebo Biotech Ag | Neue Isooxazol-Derivate und deren Verwendungen |
AU2007275301A1 (en) * | 2006-07-20 | 2008-01-24 | Amgen Inc. | Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1 |
TWI389895B (zh) | 2006-08-21 | 2013-03-21 | Infinity Discovery Inc | 抑制bcl蛋白質與結合夥伴間之交互作用的化合物及方法 |
CA2684105C (en) * | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
US20090076275A1 (en) * | 2007-09-19 | 2009-03-19 | David Robert Bolin | Diacylglycerol acyltransferase inhibitors |
US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EP2376088B1 (en) | 2008-12-23 | 2017-02-22 | Gilead Pharmasset LLC | 6-O-Substituted-2-amino-purine nucleoside phosphoramidates |
TW201031675A (en) | 2008-12-23 | 2010-09-01 | Pharmasset Inc | Synthesis of purine nucleosides |
EP2376514A2 (en) * | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nucleoside analogs |
CN102574786A (zh) | 2009-04-02 | 2012-07-11 | 默克雪兰诺有限公司 | 二氢乳清酸脱氢酶抑制剂 |
EP2236505A1 (de) * | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
CA2767288A1 (en) | 2009-07-09 | 2011-01-13 | Alembic Pharmaceuticals Limited | Novel polymorphic form of teriflunomide salts |
UY33311A (es) | 2010-03-31 | 2011-10-31 | Pharmasset Inc | Fosforamidatos de nucleosidos |
ES2591355T3 (es) | 2010-08-24 | 2016-11-28 | Algiax Pharmaceuticals Gmbh | Uso novedoso de leflunomida y malononitrilamidas |
LT2632451T (lt) | 2010-10-29 | 2018-02-12 | Algiax Pharmaceuticals Gmbh | Malononitrilamidų panaudojimas esant neuropatiniam skausmui |
WO2012110911A1 (en) | 2011-02-18 | 2012-08-23 | Alembic Pharmaceuticals Limited | Novel polymorphic form of teriflunomide |
WO2012123353A1 (en) | 2011-03-17 | 2012-09-20 | Algiax Pharmaceuticals Gmbh | Novel use of benzofuranylsulfonates |
US20140038967A1 (en) | 2011-03-17 | 2014-02-06 | Algiax Pharmaceuticals Gmbh | Novel use for imidazotriazinones |
WO2014128669A2 (en) | 2013-02-25 | 2014-08-28 | Aurigene Discovery Technologies Limited | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
WO2015029063A2 (en) * | 2013-08-30 | 2015-03-05 | Msn Laboratories Private Limited | Novel polymorph of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethyl phenyl)-amide and process for the preparation thereof |
CN105916522A (zh) | 2013-11-22 | 2016-08-31 | 建新公司 | 用于治疗神经变性疾病的新方法 |
KR102392684B1 (ko) | 2014-01-13 | 2022-04-29 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 억제제로서의 바이시클릭 헤테로시클릴 유도체 |
KR20170016500A (ko) * | 2014-06-20 | 2017-02-13 | 오리진 디스커버리 테크놀로지스 리미티드 | Irak4 저해제로서의 치환된 인다졸 화합물 |
CN105272882B (zh) * | 2014-07-23 | 2019-05-31 | 欣凯医药化工中间体(上海)有限公司 | 一种环保简便制备泰瑞米特的方法 |
RU2722316C2 (ru) * | 2015-06-17 | 2020-05-29 | Биокон Лимитед | Новый способ получения терифлуномида |
CA3053068A1 (en) | 2017-02-24 | 2018-08-30 | Merck Patent Gmbh | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors |
IL293783B2 (en) | 2017-03-31 | 2024-01-01 | Aurigene Oncology Ltd | Compounds and preparations for the treatment of hematological disorders |
US20180369206A1 (en) | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
RS62519B1 (sr) | 2017-04-24 | 2021-11-30 | Aurigene Discovery Tech Ltd | Metode upotrebe trisupstituisanih derivata benzotriazola kao inhibitora dihidroorotat oksigenaze |
PL3704108T3 (pl) | 2017-10-31 | 2024-07-22 | Curis, Inc. | Inhibitor irak4 w połączeniu z inhibitorem bcl-2 do stosowania w leczeniu nowotworu złośliwego |
TR202022336A2 (tr) | 2020-12-30 | 2022-07-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A film coated tablet comprising teriflunomide |
EP4162933A1 (en) | 2021-10-08 | 2023-04-12 | Algiax Pharmaceuticals GmbH | Compound for treating non-alcoholic fatty liver disease and related diseases |
EP4382097A1 (en) | 2022-11-25 | 2024-06-12 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet comprising teriflunomide |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL178596C (nl) * | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
DE2524959C2 (de) * | 1975-06-05 | 1983-02-10 | Hoechst Ag, 6000 Frankfurt | 5-Methyl-isoxazol-4-carbonsäureanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Mittel |
NL186239B (nl) * | 1975-06-05 | Hoechst Ag | Werkwijze voor de bereiding van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor de bereiding van een 2-hydroxyethylideencyaanazijnzuuranilide geschikt voor toepassing bij deze werkwijze. | |
DE2555789A1 (de) * | 1975-12-11 | 1977-07-07 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
DE2557003A1 (de) * | 1975-12-18 | 1977-06-23 | Hoechst Ag | Neue cyanessigsaeureanilid-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
DE2655009A1 (de) * | 1976-12-04 | 1978-06-15 | Hoechst Ag | Isoxazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
DE2854439A1 (de) * | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
DE3405727A1 (de) * | 1984-02-17 | 1985-08-22 | Hoechst Ag, 6230 Frankfurt | Isoxazol-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3534440A1 (de) * | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
GB8619432D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
GB8619433D0 (en) * | 1986-08-08 | 1986-09-17 | Lilly Industries Ltd | Pharmaceutical compounds |
US4816467A (en) * | 1987-01-09 | 1989-03-28 | Farmitalia Carlo Erba S.R.L | Heteroaryl 3-oxo-propanenitrile derivatives, pharmaceutical compositions and use |
-
1990
- 1990-10-24 DK DK90915462.7T patent/DK0527736T3/da active
- 1990-10-24 KR KR1019920702895A patent/KR100188801B1/ko not_active IP Right Cessation
- 1990-10-24 RU RU9092016445A patent/RU2084223C1/ru active
- 1990-10-24 CA CA002083179A patent/CA2083179C/en not_active Expired - Lifetime
- 1990-10-24 ES ES90915462T patent/ES2102367T3/es not_active Expired - Lifetime
- 1990-10-24 JP JP2514415A patent/JP2995086B2/ja not_active Expired - Lifetime
- 1990-10-24 RU RU94033835A patent/RU2142937C1/ru active
- 1990-10-24 AT AT90915462T patent/ATE151633T1/de not_active IP Right Cessation
- 1990-10-24 WO PCT/EP1990/001800 patent/WO1991017748A1/de active IP Right Grant
- 1990-10-24 DE DE59010701T patent/DE59010701D1/de not_active Expired - Lifetime
- 1990-10-24 EP EP90915462A patent/EP0527736B1/de not_active Expired - Lifetime
- 1990-10-24 BR BR909008022A patent/BR9008022A/pt not_active Application Discontinuation
- 1990-10-24 HU HU9203619A patent/HU222234B1/hu active IP Right Grant
- 1990-10-24 AU AU65468/90A patent/AU649421B2/en not_active Expired
- 1990-10-24 US US07/938,048 patent/US5494911A/en not_active Expired - Lifetime
- 1990-10-27 TW TW081101406A patent/TW211558B/zh active
- 1990-10-27 TW TW079109110A patent/TW205004B/zh active
-
1991
- 1991-05-16 SK SK542-99A patent/SK281318B6/sk not_active IP Right Cessation
- 1991-05-16 SK SK1450-91A patent/SK281316B6/sk not_active IP Right Cessation
- 1991-05-16 SK SK1376-98A patent/SK281317B6/sk not_active IP Right Cessation
- 1991-05-16 PT PT97689A patent/PT97689B/pt not_active IP Right Cessation
- 1991-05-16 CZ CS19911450A patent/CZ290474B6/cs not_active IP Right Cessation
- 1991-05-16 NZ NZ238165A patent/NZ238165A/en not_active IP Right Cessation
- 1991-05-16 IL IL9816391A patent/IL98163A/en not_active IP Right Cessation
- 1991-05-16 CN CN91103182A patent/CN1051074C/zh not_active Expired - Lifetime
- 1991-05-17 IE IE169491A patent/IE911694A1/en not_active IP Right Cessation
- 1991-05-20 YU YU88491A patent/YU48765B/sr unknown
-
1992
- 1992-11-17 FI FI925211A patent/FI105683B/fi active
- 1992-11-17 NO NO924433A patent/NO180118C/no not_active IP Right Cessation
-
1993
- 1993-05-07 LV LVP-93-310A patent/LV10575B/en unknown
-
1994
- 1994-03-23 AU AU57992/94A patent/AU662465B2/en not_active Expired
-
1995
- 1995-06-07 US US08/476,278 patent/US5532259A/en not_active Expired - Lifetime
- 1995-08-24 CZ CZ19952176A patent/CZ290717B6/cs not_active IP Right Cessation
- 1995-11-23 CZ CZ19953092A patent/CZ290737B6/cs not_active IP Right Cessation
- 1995-11-23 CZ CZ19953091A patent/CZ290736B6/cs not_active IP Right Cessation
-
1997
- 1997-05-30 GR GR970401284T patent/GR3023638T3/el unknown
-
1998
- 1998-09-29 CY CY9800032A patent/CY2123B1/xx unknown
-
1999
- 1999-03-01 JP JP05210799A patent/JP3201747B2/ja not_active Expired - Lifetime
- 1999-03-01 JP JP05210899A patent/JP3233610B2/ja not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1065744C (zh) * | 1994-01-07 | 2001-05-16 | 休正公司 | 对与血小板源生长因子有关的疾病如癌症的治疗 |
CN1120160C (zh) * | 1997-01-28 | 2003-09-03 | 阿文蒂斯药物德国有限公司 | 异噁唑与巴豆酰胺衍生物及其在药学和诊断学中的用途 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1056684A (zh) | 异唑-4-羧酰胺及羟基亚烷基氰乙酰胺,含有这些化合物的药物及它们的应用 | |
CN1198613C (zh) | 氨基苯氧基乙酸衍生物和含有它们的药用组合物 | |
CN1149204C (zh) | 1-杂环取代的二芳基胺 | |
CN1027588C (zh) | N-苯烷基取代的α-氨基羧基酰胺衍生物的制备方法 | |
CN1247574C (zh) | 异吲哚啉-1-酮葡糖激酶激活剂 | |
CN1027068C (zh) | α-取代的4-(喹啉-2-基-甲氧基)苯乙酸和酯的制备方法 | |
CN1035113A (zh) | 用于治疗的杂环化合物 | |
CN1094031A (zh) | 新的环己烷亚基衍生物 | |
CN100349876C (zh) | 嘧啶化合物 | |
CN1890218A (zh) | 微管蛋白抑制剂 | |
CN1741999A (zh) | 用作GSK-3β抑制剂的哒嗪酮衍生物 | |
CN1720043A (zh) | 非核苷逆转录酶抑制剂 | |
CN1006548B (zh) | 苯磺酰胺衍生物的制备方法 | |
CN1476434A (zh) | 新化合物 | |
CN1092406A (zh) | 新的环已烷和环已烯类衍生物 | |
CN1056494A (zh) | 血小板激活因子的双芳基酰胺和脲拮抗剂 | |
CN1129937A (zh) | 作为5ht2c拮抗剂的二氢吲哚衍生物 | |
CN86102761A (zh) | N-吲哚基乙基-磺酰胺类其制备方法及用途 | |
CN1807413A (zh) | 咔唑磺酰胺衍生物及其制备方法 | |
CN1894240A (zh) | 阿片受体拮抗剂 | |
CN1413205A (zh) | 具有抗肿瘤活性的2-(1h-吲哚-3-基)-2-氧代-乙酰胺 | |
CN1169797C (zh) | 抗病毒的嘧啶二酮衍生物及其制备方法 | |
CN1318051A (zh) | 带有芳香族含氮杂环的新型脲衍生物 | |
CN1099752A (zh) | 新型酰氨烷基-和亚氨烷基-哌嗪 | |
CN1283187A (zh) | 新颖二氢吡啶衍生物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
COR | Change of bibliographic data |
Free format text: CORRECT: PATENTEE; FROM: HOECHST AKTIENGESELLSCHAFT (DE) TO: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Patentee after: Awentis Medicines Deutschland GmbH Patentee before: Hechester JSC |
|
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C56 | Change in the name or address of the patentee |
Owner name: SANOFI- AVENTIS GERMAN CO., LTD. Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD. |
|
CP03 | Change of name, title or address |
Address after: Frankfurt, Germany Patentee after: Hoechst Marion Roussel de GmbH Address before: Frankfurt, Federal Republic of Germany Patentee before: Awentis Medicines Deutschland GmbH |
|
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |
Expiration termination date: 20110516 Granted publication date: 20000405 |